NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016
نویسندگان
چکیده
منابع مشابه
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include updated recommendations to the overall management of multiple myeloma from diagnosis and staging to new treatment options.
متن کاملSmoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Cigarette smoking has been implicated in causing many cancers and cancer deaths. There is mounting evidence indicating that smoking negatively impacts cancer treatment efficacy and overall survival. The NCCN Guidelines for Smoking Cessation have been created to emphasize the importance of smoking cessation and establish an evidence-based standard of care in all patients with cancer. These guide...
متن کاملMelanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and high-dose ipilimumab. Treatment options for in-tr...
متن کاملNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Myelodysplastic Syndromes
NCCN All recommendations are category 2A unless otherwise specified. See believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html. The NCCN Guidelines are a statement of evidence and consensus of t...
متن کاملNCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the National Comprehensive Cancer Network
سال: 2016
ISSN: 1540-1405,1540-1413
DOI: 10.6004/jnccn.2016.0146